Effects of Intradermal Botulinum Toxin Injections on Herpes Zoster Related Neuralgia.
botulinum toxin
herpes zoster
postherpetic neuralgia
Journal
Infection and drug resistance
ISSN: 1178-6973
Titre abrégé: Infect Drug Resist
Pays: New Zealand
ID NLM: 101550216
Informations de publication
Date de publication:
2023
2023
Historique:
received:
19
12
2022
accepted:
17
03
2023
medline:
20
4
2023
pubmed:
20
4
2023
entrez:
20
04
2023
Statut:
epublish
Résumé
Postherpetic neuralgia (PHN), which represents the most common chronic complication of herpes zoster, is characterized by intense pain and is difficult to treat. In fact, no treatments are currently available that can effectively reduce the pain associated with PHN. Recent evidence has been presented indicating that Botulinum toxin (BoNT-A) can serve as an effective and safe treatment for peripheral neuropathic pain. The effects of intradermal BoNT-A injections on herpes zoster related neuralgia were investigated in this study. Patients diagnosed with herpes zoster related acute neuralgia (N=13 - acute group) and those diagnosed with postherpetic neuralgia (N=17 - PHN group) were enrolled in this study. The two groups were treated with intradermal injections of BoNT-A at the site of their affected pain areas and were then assessed at 1 day, 1 week, 2 weeks, 1 month, 2 months and 3 months after their BoNT-A treatments. When compared with pre-treatment values, Visual Analogue Scores (VAS) in all patients were all significantly decreased at all times tested following BoNT-A injection. Before treatment, PHN patients had significantly higher VAS than those in the acute group. However, after 1 day of treatment, there was no difference in VAS between the two groups. None of the patients in the acute phase treated with BoNT-A developed PHN. BoNT-A injections significantly reduced herpetic-related pain and proved to be a more effective treatment for the PHN versus acute pain group. Moreover, an early application of BoNT-A can alleviate the probability of developing PHN.
Sections du résumé
Background
UNASSIGNED
Postherpetic neuralgia (PHN), which represents the most common chronic complication of herpes zoster, is characterized by intense pain and is difficult to treat. In fact, no treatments are currently available that can effectively reduce the pain associated with PHN. Recent evidence has been presented indicating that Botulinum toxin (BoNT-A) can serve as an effective and safe treatment for peripheral neuropathic pain.
Objective
UNASSIGNED
The effects of intradermal BoNT-A injections on herpes zoster related neuralgia were investigated in this study.
Methods
UNASSIGNED
Patients diagnosed with herpes zoster related acute neuralgia (N=13 - acute group) and those diagnosed with postherpetic neuralgia (N=17 - PHN group) were enrolled in this study. The two groups were treated with intradermal injections of BoNT-A at the site of their affected pain areas and were then assessed at 1 day, 1 week, 2 weeks, 1 month, 2 months and 3 months after their BoNT-A treatments.
Results
UNASSIGNED
When compared with pre-treatment values, Visual Analogue Scores (VAS) in all patients were all significantly decreased at all times tested following BoNT-A injection. Before treatment, PHN patients had significantly higher VAS than those in the acute group. However, after 1 day of treatment, there was no difference in VAS between the two groups. None of the patients in the acute phase treated with BoNT-A developed PHN.
Conclusion
UNASSIGNED
BoNT-A injections significantly reduced herpetic-related pain and proved to be a more effective treatment for the PHN versus acute pain group. Moreover, an early application of BoNT-A can alleviate the probability of developing PHN.
Identifiants
pubmed: 37077249
doi: 10.2147/IDR.S401972
pii: 401972
pmc: PMC10106788
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2159-2165Informations de copyright
© 2023 Peng and Xia.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest in this work.
Références
Pain. 2010 May;149(2):316-324
pubmed: 20223589
Toxins (Basel). 2022 Jun 14;14(6):
pubmed: 35737067
Diabetes Metab Syndr. 2020 Nov-Dec;14(6):1823-1828
pubmed: 32961514
Anesth Analg. 2017 Aug;125(2):643-652
pubmed: 28731977
Perspect Biol Med. 1997 Spring;40(3):317-27
pubmed: 9167258
Clin J Pain. 2013 Oct;29(10):857-64
pubmed: 23370074
Medicina (Kaunas). 2022 Jun 16;58(6):
pubmed: 35744076
Eur J Pain. 2022 May;26(5):980-990
pubmed: 35293078
Front Neurol. 2020 Aug 11;11:716
pubmed: 32849195
Microorganisms. 2022 Apr 24;10(5):
pubmed: 35630331
Acta Derm Venereol. 2009;89(2):214-5
pubmed: 19326024
Toxins (Basel). 2022 Jan 03;14(1):
pubmed: 35051013
Evid Based Complement Alternat Med. 2022 Jul 4;2022:4478444
pubmed: 35832527
Viruses. 2022 Jan 19;14(2):
pubmed: 35215786
J Neuroimmunol. 2022 Mar 15;364:577792
pubmed: 35030439
Hautarzt. 2016 Aug;67(8):653-65
pubmed: 27389412
Toxins (Basel). 2022 Apr 27;14(5):
pubmed: 35622555
J Am Acad Dermatol. 2016 Sep;75(3):572-577
pubmed: 27543213
Toxins (Basel). 2022 May 31;14(6):
pubmed: 35737044
N Engl J Med. 1996 Jul 4;335(1):32-42
pubmed: 8637540
Neurologia. 2008 May;23(4):259-62
pubmed: 18516748
Oral Surg Oral Med Oral Pathol Oral Radiol. 2016 Jul;122(1):61-71
pubmed: 27260275
Toxins (Basel). 2012 Oct;4(10):913-39
pubmed: 23162705
Nature. 1992 Jan 2;355(6355):75-8
pubmed: 1370574
Clin Exp Ophthalmol. 2014 Apr;42(3):254-61
pubmed: 23844601
Pain Med. 2006 Jan-Feb;7(1):89-91
pubmed: 16533208
Neurology. 2016 Jul 5;87(1):94-102
pubmed: 27287218
J Am Acad Dermatol. 2007 Dec;57(6 Suppl):S136-42
pubmed: 18021865
Toxins (Basel). 2015 Jun 30;7(7):2454-80
pubmed: 26134256
Pain Med. 2013 Aug;14(8):1202-11
pubmed: 23710678